Our Technology
TianTi Bio Beats the Antibody Challenge
Antibody discovery can be one of medical research's greatest challenges. TianTi Bio offers new confidence in antibody discovery with our AbLink,™ OptAb,™ and Rapid VHH platforms. Together these research technologies provide end-to-end capabilities for delivering antibody drug candidates quickly and efficiently.
Our Ablink™ Platform
The AbLink™ platform screens the entire natural immune repertoire with unprecedented scale and acute sensitivity, revealing clones that would otherwise be undiscoverable. By boosting research possibilities, TianTi Bio delivers greater antibody discovery success for challenging targets.
AbLink™ Workflow: Building Naturally Paired Libraries from Immunized Animal and Human Peripheral Bloods
Our AbLink™ platform screens the natural immune repertoire with both unprecedented scale and sensitivity. The platform captures up to 108 single B cells and produces naturally paired VH-VL products. These VH-VL amplicons are transformed into yeast cells with switchable display and secretion modes. The dual mode enables rapid identification, isolation, and characterization of a large panel of diverse, high functional antibodies.
How AbLink™ Compares to Other Natural Immune Repertoire Screening Technologies
TianTi Bio’s natural selection revolution
The maximum diversity of natural antibodies in animal and humans is dynamic and can reach as high as 1018. However, the luxury of having great diversity in natural antibodies means most desired clones are low in frequency, making these desired clones extremely rare. Current available technologies can only screen a small fraction of the natural antibody repertoire, leaving most of the repertoire - and rare clones – untapped.
Our AbLink™ platform screens the entire natural immune repertoire with unprecedented scale and acute sensitivity, revealing rare clones that would otherwise be undiscoverable. By boosting research possibilities, TianTi Bio delivers greater levels of scientific success for challenging targets.
Deep mining of natural immune repertoire increases the probability of discovering optimal antibodies
Natural Pairing Wins Over Random Pairing in Expression
In monoclonal yeast supernatants, naturally paired antibodies have significantly superior expression profiles compared to those randomly paired.
Our Unique quick-hits characterization process
The secretion mode of the AbLink™ platform enables rapid hits characterization including high throughput affinity ranking. It also includes antigen binding confirmation, specificity, cross reactivity determination, and functional validation.
Unique to AbLink™: Rigorous Screening Strategy Enriches Rare Clones in Immune Repertoire
AbLink™ platform identifies rare clones that were not readily discovered by other platforms.
Our OptAb™ Platform
OptAb™ offers three-in-one efficiency with concurrent high throughput antibody humanization, optimization, and affinity maturation.
In silicon modeling has its applications, but it still requires accurate structure information and an existing database for antibody affinity maturation, optimization, and humanization. Unfortunately, often this intelligence is unavailable or structure predictions are inaccurate, leaving only a few mutated variants for testing which ultimately leads to poor-quality results.
TianTi Bio overcomes these barriers using processes that far surpass a small handful of sequences. For example, the antibody maybe humanized, or hot spots are fixed, but affinity or efficacy is compromised. In this scenario we design large de novo libraries and conduct screening using high throughput technologies for significantly faster and more successful results.
During the de novo library design process, we leverage sequence information from our Ablink platform. Using Ablink data, we align multiple sequences to better predict which residues are potentially involved in binding affinity. We then incorporate this key information into our OptAb library design.
The most effective research results are possible when our technologies are used synergistically. Studies demonstrate we successfully achieve humanization, optimization, and affinity maturation simultaneously which is unachievable by in silicon modeling alone.
Our Rapid VHH Platform
TianTi Bio's Rapid VHH technology delivers high-quality VHH antibody discovery providing optimal results in minimal time. We make screening easier with yeast that is specially engineered to express VHH at the highest levels. In addition, our VHH library construction directly captures the natural diversity of Llama and Alpaca immune response. Various custom-specific selection strategies can be used to rapidly isolate desired VHH hits saving time and effort.
Chinese